ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /化合物

An inositol

HCID 892
ノートを作成反応を作成見積依頼を出す
印刷プレビュー

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
38876-99-2
標準SMILES
OC1C(O)C(O)C(O)C(O)C1O
InChIKey
CDAISMWEOUEBRE-UHFFFAOYSA-N
分子式
C6H12O6
平均分子量
180.16 g/mol
単同位体質量
180.0633881

概要

Myo-inositol is an inositol having myo- configuration. It has a role as a member of compatible osmolytes, a nutrient, an EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor, a mouse metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite, a human metabolite and a Daphnia magna metabolite.

名称と識別子

優先名称
An inositol
IUPAC
cyclohexane-1,2,3,4,5,6-hexol
英語名
1L-chiro-Inositol
分子式
C6H12O6
分子量
180.16

名称と別名

an inositolRefChem:1076961inositolScyllo-inositolmyo-inositolMuco-Inositolepi-InositolAllo-inositolD-chiro-Inositoli-Inositol87-89-8meso-Inositol
名称をさらに表示
643-12-91D-Chiro-inositolNeo-inositol488-59-5D-(+)-chiro-Inositolcis-Inositol1L-Chiro-inositol6917-35-7

データベース識別子

CAS
38876-99-2、488-54-0、488-55-1、488-58-4、488-59-5、551-72-4、576-63-6、643-10-7、643-12-9、6917-35-7、87-89-8
PubChem CID
892
DTXSID
DTXSID30110000
ChEMBL
CHEMBL1231671、CHEMBL1950780、CHEMBL278373、CHEMBL3976780
ChEBI
CHEBI:17268
UNII
1VS4X81277、4661D3JP8D、4L6452S749、587A93P465、63GQX5QW03、6R79WV4R10、8LQ63P85IC、9O6Y5O4P9W、M94176HJ2F、R1Y9F3N15A
EC Number
207-681-5、209-000-7、211-393-5、211-394-0
Nikkaji
J101.888D、J101.889B、J101.890F、J101.891D、J101.892B、J4.282J、J522.945F、J9.771C、J92.778C

物性

構造計算による物性補完中

XLogP
-3.7
極性表面積
121 Ų
水素結合供与体数
6
水素結合受容体数
6
回転可能結合数
0
重原子数
12
形式電荷
0
複雑度
104

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
CosmeticsHair conditioning; Humectant; Antistatic
Animal DrugsPharmaceuticals -> UK Veterinary Medicines Directorate List
Collision Cross Section · 5 件

131.3 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

128.61 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

144.27 Ų [M-H]- [CCS Type: DT; Method: stepped-field]

138.63 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

148.7 Ų [M+Na]+

物理化学的性質

沸点
291.3 · 291.3±40.0 °C(Predicted)
比重(密度)
2.038 · 2.038±0.06 g/cm3(Predicted)
酸解離定数(Pka)
12.63 · 12.63±0.70(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 6 件

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

This chemical does not meet GHS hazard criteria for 100% (4 of 4) of all reports.

Not Classified

危険有害性情報

Regulatory Information · 6 件

neo-Inositol: Does not have an individual approval but may be used under an appropriate group standard

muco-Inositol: Does not have an individual approval but may be used under an appropriate group standard

L-chiro-Inositol: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

cis-Inositol: Does not have an individual approval but may be used under an appropriate group standard

allo-Inositol: Does not have an individual approval but may be used under an appropriate group standard

D-chiro-Inositol: Does not have an individual approval but may be used under an appropriate group standard

Hazard Classes and Categories · 2 件

Skin Irrit. 2 (100%)

Not Classified

化学と産業

薬理情報

Protein BindingIt is thought that inositol can be found bound to plasma proteins.
Pharmacodynamics · 1 件

Inositol can stimulate glucose uptake in skeletal muscle cells which allows the decrease in blood sugar levels. This effect is later seen as a reduction in urine glucose concentration and indicates a decrease in high blood sugar levels. In PCOS, the administration of inositol has produced the remission of symptoms as well as a reduction in male hormone secretion, a regulation of the cholesterol level, and a more efficient fat breakdown which allow to a significant reduction on body mass and appetite. In the cases of infertility, inositol has been proven to increase sperm count and motility, as well as increase the overall quality of oocytes and embryos. In the brain, inositol has been shown to produce an increase in serotonin receptor sensitivity. This activity produces an increase in GABA release. Some of the effects observed in the brain produced a relief in symptoms of anxiety and obsessive-compulsive disorders. In high doses, it has been shown to even reduce panic attacks. In cancer research, inositol has gained interest as it can act as an antioxidant, anti-inflammatory and it seems to enhance immune properties.

Mechanism of Action · 1 件

The mechanism of action of inositol in brain disorders is not fully understood but it is thought that it may be involved in neurotransmitter synthesis and it is a precursor to the phosphatidylinositol cycle. The change that occurs in the cycle simulates when the postsynaptic receptor is activated but without activating the receptor. This activity provokes a fake activation which regulated the activity of monoamines and other neurotransmitters. Reports have shown that insulin resistance plays a key role in the clinical development of PCOS. The presence of hyperinsulinemia can induce an excess in androgen production by stimulating ovaries to produce androgens and by reducing the sex hormone binding globulin serum levels. One of the mechanisms of insulin deficiency is thought to be related to a deficiency in inositol in the inositolphosphoglycans. The administration of inositol allows it to act as a direct messenger of the insulin signaling and improves glucose tissue uptake. This mechanism is extrapolated to its functions in diabetes treatment, metabolic syndrome, and weight loss. In cancer, the mechanism of action of inositol is not fully understood. It is hypothesized that the administration of inositol increases the level of lower-phosphate inositol phosphates why can affect cycle regulation, growth, and differentiation of malignant cells. On the other hand, the formation of inositol hexaphosphate after administration of inositol presents antioxidant characteristics by the chelation of ferric ions and suppression of hydroxyl radicals.

関連反応

27 件
反応記録を作成
HRID 6617 の反応式
HRID 6617生成物としてuspto-grants-2006_08
HRID 20720 の反応式
HRID 20720生成物としてuspto-grants-2010_06
HRID 20721 の反応式
HRID 20721生成物としてuspto-grants-2010_06
HRID 161509 の反応式
HRID 161509反応物としてTraining data from https://doi.org/10.1039/C8SC04228D (9/10)
HRID 339163 の反応式
HRID 339163反応物としてuspto-grants-2014_11
HRID 353024 の反応式
HRID 353024反応物としてuspto-grants-2004_06
HRID 840522 の反応式
HRID 840522反応物としてuspto-grants-2002_04
HRID 1019480 の反応式
HRID 1019480生成物としてuspto-grants-2014_05
1 / 4 ページ

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
その他の操作
ノートを作成反応を作成見積依頼を出す
Biological Half-LifeThe pharmacokinetic profile of inositol was studied in preterm infants and the estimated elimination half-life was reported to be of 5.22 hours.
Metabolism/Metabolites · 1 件

It is thought that inositol is metabolized to phosphoinositol and then converted to phosphatylinositol-4,5-biphosphate which is a precursor of the second-messenger molecules. Inositol can be transformed to D-chiro-inositol via the actions of an epimerase. The normal modifications to inositol structure seem to be between all the different isomers.

Absorption, Distribution and Excretion · 4 件

Inositol is absorbed from the small intestine. In patients with inositol deficiency, the maximal plasma concentration after oral administration of inositol is registered to be of 4 hours. Inositol is taken up by the tissues via sodium-dependent inositol co-transporter which also mediates glucose uptake. Oral ingestion of inositol is registered to generate a maximal plasma concentration of 36-45 mcg.

Most of the administered dose is excreted in urine.

The pharmacokinetic profile of inositol was studied in preterm infants and the estimated volume of distribution was reported to be 0.5115 L/kg.

The pharmacokinetic profile of inositol was studied in preterm infants and the estimated clearance rate was reported to be 0.0679 L.kg/h.

用途と製造

Use ClassificationCosmetics -> Hair conditioning; Humectant; Antistatic

上流・下流製品情報

下流製品

フィチン酸